TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?
Brief Summary: This study will assess how the current VHV (VHV=CHW, community health worker) scope can be expanded to include iCCM and if such group interventions can provide improved access to treatment for children.

In rural SW Uganda, can iCCM provided by lay volunteers, increase the proportion of children with diarrhoea receiving ORS/Zn, ARI receiving anti-biotics, and fever/malaria receiving anti-malarials?


Options:
A: Arm Label: Rapid Diagnostic Test; Type: EXPERIMENTAL; Interventions: Procedure: Rapid Diagnostic Test | Arm Label: No RDT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Rapid Diagnostic Test; Assigned to Arm(s): Rapid Diagnostic Test
B: Arm Label: Training of VHVs in iCCM; Type: EXPERIMENTAL; Interventions: Other: Training of VHVs in iCCM | Intervention Type: OTHER; Name: Training of VHVs in iCCM; Assigned to Arm(s): Training of VHVs in iCCM
C: Arm Label: rapid diagnostic test; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test, Drug: Lumartem | Arm Label: Presumptive malaria treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Rapid diagnostic test; Assigned to Arm(s): rapid diagnostic test | Intervention Type: DRUG; Name: Lumartem; Assigned to Arm(s): rapid diagnostic test
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Rapid diagnostic test for malaria | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test for malaria | Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?
Brief Summary: This study will assess how the current VHV (VHV=CHW, community health worker) scope can be expanded to include iCCM and if such group interventions can provide improved access to treatment for children.

In rural SW Uganda, can iCCM provided by lay volunteers, increase the proportion of children with diarrhoea receiving ORS/Zn, ARI receiving anti-biotics, and fever/malaria receiving anti-malarials?


Options:
A: Arm Label: Training of VHVs in iCCM; Type: EXPERIMENTAL; Interventions: Other: Training of VHVs in iCCM | Intervention Type: OTHER; Name: Training of VHVs in iCCM; Assigned to Arm(s): Training of VHVs in iCCM
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Coartem and amoxicillin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem | Intervention Type: DRUG; Name: Coartem and amoxicillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coartem; Assigned to Arm(s): 2
C: Arm Label: Amoxicillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin | Arm Label: Sugar Syrup; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sugar Syrup | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin | Intervention Type: DRUG; Name: Sugar Syrup; Assigned to Arm(s): Sugar Syrup
D: Arm Label: Bundled RMNCH Intervention; Type: EXPERIMENTAL; Interventions: Other: Community Health Worker, Other: Continuous Surveillance, Other: CB-Integrated Management of Newborn and Childhood Illness, Other: Group Antenatal and Postnatal Care, Other: Balanced Post-Partum Contraceptive Counseling | Intervention Type: OTHER; Name: Community Health Worker; Assigned to Arm(s): Bundled RMNCH Intervention | Intervention Type: OTHER; Name: Continuous Surveillance; Assigned to Arm(s): Bundled RMNCH Intervention | Intervention Type: OTHER; Name: CB-Integrated Management of Newborn and Childhood Illness; Assigned to Arm(s): Bundled RMNCH Intervention | Intervention Type: OTHER; Name: Group Antenatal and Postnatal Care; Assigned to Arm(s): Bundled RMNCH Intervention | Intervention Type: OTHER; Name: Balanced Post-Partum Contraceptive Counseling; Assigned to Arm(s): Bundled RMNCH Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?
Brief Summary: This study will assess how the current VHV (VHV=CHW, community health worker) scope can be expanded to include iCCM and if such group interventions can provide improved access to treatment for children.

In rural SW Uganda, can iCCM provided by lay volunteers, increase the proportion of children with diarrhoea receiving ORS/Zn, ARI receiving anti-biotics, and fever/malaria receiving anti-malarials?


Options:
A: Arm Label: Training of VHVs in iCCM; Type: EXPERIMENTAL; Interventions: Other: Training of VHVs in iCCM | Intervention Type: OTHER; Name: Training of VHVs in iCCM; Assigned to Arm(s): Training of VHVs in iCCM
B: Arm Label: Integrated mental health in primary care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated mental health in primary care | Arm Label: Psychiatric nurse-led specialist care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric nurse-led specialist care | Intervention Type: BEHAVIORAL; Name: Integrated mental health in primary care; Assigned to Arm(s): Integrated mental health in primary care | Intervention Type: BEHAVIORAL; Name: Psychiatric nurse-led specialist care; Assigned to Arm(s): Psychiatric nurse-led specialist care
C: Arm Label: nothing at home level; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home management of malaria; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Arm Label: Home management of malaria and pneumonia; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Intervention Type: OTHER; Name: home/community case management; Assigned to Arm(s): Home management of malaria, Home management of malaria and pneumonia
D: Arm Label: ICCM delivered by VHT; Type: ACTIVE_COMPARATOR; Interventions: Other: ICCM delivered by VHT | Arm Label: ICCM delivered by VHT with cell phone; Type: ACTIVE_COMPARATOR; Interventions: Other: ICCM delivered by VHT, Other: ICCM delivered by VHT with Cell Phone | Arm Label: Health outcomes in communities with no ICCM; Type: ACTIVE_COMPARATOR; Interventions: Other: No intervention | Intervention Type: OTHER; Name: ICCM delivered by VHT; Assigned to Arm(s): ICCM delivered by VHT, ICCM delivered by VHT with cell phone | Intervention Type: OTHER; Name: ICCM delivered by VHT with Cell Phone; Assigned to Arm(s): ICCM delivered by VHT with cell phone | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Health outcomes in communities with no ICCM

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Brief Summary: This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to \<4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): B
B: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: levetiracetam | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: levetiracetam; Assigned to Arm(s): A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 150 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 150 mg/day
D: Arm Label: Study Drug Level 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin Dose Level 1 | Arm Label: Study Drug Level 2; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin Dose Level 2 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin Dose Level 1; Assigned to Arm(s): Study Drug Level 1 | Intervention Type: DRUG; Name: Pregabalin Dose Level 2; Assigned to Arm(s): Study Drug Level 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making
Brief Summary: In partnership with patients, caregivers, advocacy groups and clinicians, the investigators plan to:

Aim 1: Adapt and refine PREPARE in Spanish through cognitive interviews with Spanish-speaking Latinos and stakeholders.

Aim 2: Conduct a randomized clinical trial (RCT) to compare the efficacy of PREPARE plus a previously-tested, easy-to-read- AD (intervention) versus the AD alone (control) to:

2a. Engage older Spanish-speaking Latinos in multiple ACP behaviors (i.e., identify and discuss wishes with surrogates and clinicians and complete ADs) measured by self-report, chart review, surrogate reports, and

2b. Direct observation.

2c. Improve self-efficacy and satisfaction with medical decision making.

2d. Determine whether PREPARE efficacy varies by literacy, decision control preferences, and clinician-patient language concordance.

Aim 3: Disseminate PREPARE with input from patients, surrogates, and stakeholders.


Options:
A: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
B: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention
C: Arm Label: Telephonic Diabetes Self-Management Support; Type: EXPERIMENTAL; Interventions: Behavioral: Telephonic Diabetes Self-Management Support | Arm Label: Educational Print Materials; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Print Materials | Intervention Type: BEHAVIORAL; Name: Telephonic Diabetes Self-Management Support; Assigned to Arm(s): Telephonic Diabetes Self-Management Support | Intervention Type: OTHER; Name: Educational Print Materials; Assigned to Arm(s): Educational Print Materials
D: Arm Label: Usual education (standard care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensive initial education; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive initial education | Intervention Type: BEHAVIORAL; Name: Intensive initial education; Assigned to Arm(s): Intensive initial education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Home Fortification With Two Iron Formulations in Kenyan Children Protected Against Malaria by Artemisinin-based Combination Therapy: a Placebo-controlled Non-inferiority Trial
Brief Summary: This study will determine whether the haemoglobin response to daily home fortification for 30 days with 3mg iron as NaFeEDTA is non-inferior to 12.5 mg iron as encapsulated ferrous fumarate.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Wheat Soya Blend (WSB), Dietary Supplement: Wawa Mum, Dietary Supplement: Micronutrient Powders (MNP), Behavioral: Behavior change and preventive health massages | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat Soya Blend (WSB); Assigned to Arm(s): Intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: Wawa Mum; Assigned to Arm(s): Intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Powders (MNP); Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Behavior change and preventive health massages; Assigned to Arm(s): Intervention
B: Arm Label: Vitamin/mineral fortificant with iron; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sprinkles® | Arm Label: Vitamin/mineral fortificant without iron; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin/mineral fortificant without iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Sprinkles®; Assigned to Arm(s): Vitamin/mineral fortificant with iron | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin/mineral fortificant without iron; Assigned to Arm(s): Vitamin/mineral fortificant without iron
C: Arm Label: Maize porridge with Amaranth; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize flour with multiple micronutrients; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize Porridge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize and Amaranth; Assigned to Arm(s): Maize Porridge, Maize flour with multiple micronutrients, Maize porridge with Amaranth
D: Arm Label: Low-dose iron as NaFeEDTA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Low-dose iron as NaFeEDTA | Arm Label: Conventional dose iron as ferrous salt; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Conventional dose iron as ferrous salt | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Low-dose iron as NaFeEDTA; Assigned to Arm(s): Low-dose iron as NaFeEDTA | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional dose iron as ferrous salt; Assigned to Arm(s): Conventional dose iron as ferrous salt | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Brief Summary: The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
C: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
D: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Brief Summary: The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.


Options:
A: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
B: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer
Brief Summary: The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.


Options:
A: Arm Label: Dabigatran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran | Arm Label: Rivaroxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban | Arm Label: Nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nadroparin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin
B: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group

Answer: D